AveXis Garners $10,000,000 New Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    4925 Greenville Avenue Dallas, TX 75206 USA
  • Company Description
    Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds from the financing will be used to further the development of the Company’s gene therapy product, chariSMATM, including additional support for the current Phase I clinical trial in SMA Type 1 infants.
  • M&A Terms
  • Venture Investor
  • Venture Investor

Trending on Xconomy